Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts

Journal of Immunology

Volumn 193, Issue 1, 2014, Pages 48-55

  Onda, Masanori ^a   Ghoreschi, Kamran ^b,d   Steward Tharp, Scott ^b,e   Thomas, Craig ^c   O'Shea, John J ^b   Pastan, Ira H ^a   FitzGerald, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIGEN TYPE 2; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; IMMUNOTOXIN; INTERLEUKIN 7 RECEPTOR; KEYHOLE LIMPET HEMOCYANIN; MACROGOL; MACROGOL 300; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; TOFACITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; BACTERIAL TOXINS; EXOTOXINS; FEMALE; GERMINAL CENTER; HEMOCYANIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTOXINS; JANUS KINASES; MICE; MICE, INBRED BALB C; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; VIRULENCE FACTORS;

EID: 84903627028     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400063     Document Type: Article

References (44)

1. Pastan, I., R. Hassan, D. J. Fitzgerald, and R. J. Kreitman. 2006. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6: 559-565.
2. Chaudhary, V. K., C. Queen, R. P. Junghans, T. A. Waldmann, D. J. FitzGerald, and I. Pastan. 1989. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339: 394-397. (Pubitemid 19144230)
3. Kreitman, R. J., W. H. Wilson, K. Bergeron, M. Raggio, M. Stetler-Stevenson, D. J. FitzGerald, and I. Pastan. 2001. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345: 241-247.
4. Wayne, A. S., R. J. Kreitman, H. W. Findley, G. Lew, C. Delbrook, S. M. Steinberg, M. Stetler-Stevenson, D. J. Fitzgerald, and I. Pastan. 2010. Anti- CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin. Cancer Res. 16: 1894-1903.
5. Kreitman, R. J., W. H. Wilson, J. D. White, M. Stetler-Stevenson, E. S. Jaffe, S. Giardina, T. A. Waldmann, and I. Pastan. 2000. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18: 1622-1636.
6. Kreitman, R. J., R. Hassan, D. J. Fitzgerald, and I. Pastan. 2009. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer Res. 15: 5274-5279.
7. Hassan,R., S.Bullock,A. Premkumar,R. J. Kreitman,H.Kindler,M.C. Willingham, and I. Pastan. 2007. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelinexpressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13: 5144-5149.
8. Zhang, Y. J., L. M. Xiang, R. Hassan, and I. Pastan. 2007. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc. Natl. Acad. Sci. USA 104: 17099-17104.
9. Zhang, Y., L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B. S. Jang, N. Le, M. Ho, and I. Pastan. 2006. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin. Cancer Res. 12: 4695-4701.
10. Kreitman, R. J., M. Stetler-Stevenson, I. Margulies, P. Noel, D. J. Fitzgerald, W. H. Wilson, and I. Pastan. 2009. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 27: 2983-2990.
11. Tsutsumi, Y., M. Onda, S. Nagata, B. Lee, R. J. Kreitman, and I. Pastan. 2000. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97: 8548-8553.
12. Onda, M., R. Beers, L. Xiang, S. Nagata, Q. C. Wang, and I. Pastan. 2008. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. USA 105: 11311-11316.
13. Onda, M., R. Beers, L. Xiang, B. Lee, J. E. Weldon, R. J. Kreitman, and I. Pastan. 2011. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc. Natl. Acad. Sci. USA 108: 5742-5747.
14. Liu, W., M. Onda, B. Lee, R. J. Kreitman, R. Hassan, L. Xiang, and I. Pastan. 2012. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. USA 109: 11782-11787.
15. Mossoba, M. E., M. Onda, J. Taylor, P. R. Massey, S. Treadwell, E. Sharon, R. Hassan, I. Pastan, and D. H. Fowler. 2011. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin. Cancer Res. 17: 3697-3705.
16. Garcês, S., J. Demengeot, and E. Benito-Garcia. 2013. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 72: 1947-1955.
17. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Janus kinases in immune cell signaling. Immunol. Rev. 228: 273-287.
18. Levy, D. E., and J. E. Darnell, Jr. 2002. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3: 651-662.
19. Shuai, K., and B. Liu. 2003. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3: 900-911.
20. Borie, D. C., J. J. O'Shea, and P. S. Changelian. 2004. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol. Med. 10: 532-541.
21. Pesu, M., A. Laurence, N. Kishore, S. H. Zwillich, G. Chan, and J. J. O'Shea. 2008. Therapeutic targeting of Janus kinases. Immunol. Rev. 223: 132-142.
22. Changelian, P. S., M. E. Flanagan, D. J. Ball, C. R. Kent, K. S. Magnuson, W. H. Martin, B. J. Rizzuti, P. S. Sawyer, B. D. Perry, W. H. Brissette, et al. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878. (Pubitemid 37339629)
23. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10: 356-360.
24. Ghoreschi, K., M. I. Jesson, X. Li, J. L. Lee, S. Ghosh, J. W. Alsup, J. D. Warner, M. Tanaka, S. M. Steward-Tharp, M. Gadina, et al. 2011. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186: 4234-4243.
25. van Vollenhoven, R. F., R. Fleischmann, S. Cohen, E. B. Lee, J. A. García Meijide, S. Wagner, S. Forejtova, S. H. Zwillich, D. Gruben, T. Koncz, et al; ORAL Standard Investigators. 2012. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367: 508-519.
26. Papp, K. A., A. Menter, B. Strober, R. G. Langley, M. Buonanno, R. Wolk, P. Gupta, S. Krishnaswami, H. Tan, and J. A. Harness. 2012. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 167: 668-677.
27. Jiang, J. K., K. Ghoreschi, F. Deflorian, Z. Chen, M. Perreira, M. Pesu, J. Smith, D. T. Nguyen, E. H. Liu, W. Leister, et al. 2008. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl- 3-(methyl(7Hpyrrolo[ 2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile (CP- 690,550). J. Med. Chem. 51: 8012-8018.
28. Onda, M., S. Nagata, Y. Tsutsumi, J. J. Vincent, Q. Wang, R. J. Kreitman, B. Lee, and I. Pastan. 2001. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 61: 5070-5077. (Pubitemid 32681537)
29. Onda, M., M. Willingham, S. Nagata, T. K. Bera, R. Beers, M. Ho, R. Hassan, R. J. Kreitman, and I. Pastan. 2005. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin. Cancer Res. 11: 5840-5846.
30. Slack, J., G. P. Der-Balian, M. Nahm, and J. M. Davie. 1980. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymusindependent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J. Exp. Med. 151: 853-862.
31. Kudlacz, E., B. Perry, P. Sawyer, M. Conklyn, S. McCurdy, W. Brissette, M. Flanagan And, and P. Changelian. 2004. The novel JAK-3 inhibitor CP- 690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 4: 51-57.
32. Nosaka, T., J. M. van Deursen, R. A. Tripp, W. E. Thierfelder, B. A. Witthuhn, A. P. McMickle, P. C. Doherty, G. C. Grosveld, and J. N. Ihle. 1995. Defective lymphoid development in mice lacking Jak3. Science 270: 800-802.
33. Thomis, D. C., C. B. Gurniak, E. Tivol, A. H. Sharpe, and L. J. Berg. 1995. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270: 794-797.
34. Nagasawa, T. 2006. Microenvironmental niches in the bone marrow required for B-cell development. Nat. Rev. Immunol. 6: 107-116.
35. Erlandsson, L., S. Licence, F. Gaspal, S. Bell, P. Lane, A. E. Corcoran, and I. L. Mårtensson. 2004. Impaired B-1 and B-2 B cell development and atypical splenic B cell structures in IL-7 receptor-deficient mice. Eur. J. Immunol. 34: 3595-3603.
36. Kikuchi, K., A. Y. Lai, C. L. Hsu, and M. Kondo. 2005. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J. Exp. Med. 201: 1197-1203.
37. Borge, O. J., J. Adolfsson, A. Mårtensson, I. L. Mårtensson, and S. E. Jacobsen. 1999. Lymphoid-restricted development from multipotent candidate murine stem cells: distinct and complimentary functions of the c-kit and flt3-ligands. Blood 94: 3781-3790.
38. Peschon, J. J., P. J. Morrissey, K. H. Grabstein, F. J. Ramsdell, E. Maraskovsky, B. C. Gliniak, L. S. Park, S. F. Ziegler, D. E. Williams, C. B. Ware, et al. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptordeficient mice. J. Exp. Med. 180: 1955-1960.
39. Mazzucchelli, R., and S. K. Durum. 2007. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7: 144-154.
40. Scott, L. J. 2013. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 73: 857-874.
41. Weldon, J. E., L. Xiang, J. Zhang, R. Beers, D. A. Walker, M. Onda, R. Hassan, and I. Pastan. 2013. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol. Cancer Ther. 12: 48-57.
42. Menges, C. W., Y. Chen, B. T. Mossman, J. Chernoff, A. T. Yeung, and J. R. Testa. 2010. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 1: 493-505.
43. Leonard, W. J., E. W. Shores, and P. E. Love. 1995. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol. Rev. 148: 97-114.
44. Xia, J. Q., D. A. Rickaby, K. J. Kelly, H. Choi, C. A. Dawson, and V. P. Kurup. 1999. Immune response and airway reactivity in wild and IL-4 knockout mice exposed to latex allergens. Int. Arch. Allergy Immunol. 118: 23-29.